BioMedNewsBreaks – ROTH’s Healthcare Opportunities Conference to Showcase ~25 Carefully Selected Companies

ROTH Capital Partners, a full service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its Inaugural Healthcare Opportunities Conference in New York City on Oct. 6, 2022. The conference will feature approximately 25 public healthcare companies that have been selected by ROTH’s research analysts and provide C-level executives the opportunity to closely interact with pre-qualified institutional investors and healthcare industry professionals. The event will have a multiple sub-sector focus with participating companies operating in biotechnology, pharmaceuticals, medical technologies, oncology and mental health therapeutics. “Most healthcare conferences are skewed toward companies whose market capitalizations are quite large,” said Tony Butler, Ph.D., managing director, senior research analyst and head of biotechnology research. “Investments may be crowded. Our conference offers opportunities for investors to possibly generate higher alpha within their portfolios.”

To view the full press release, visit https://ibn.fm/sQiI3

About ROTH Capital Partners LLC

ROTH Capital Partners is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, California, ROTH is privately held and owned by its employees and maintains offices throughout the U.S. For more information on ROTH, please visit www.ROTH.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution

Oragenics (NYSE American: OGEN) announced that it has engaged DUCK FLATS Pharma as its U.S.…

33 minutes ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced…

1 day ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan

NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on…

1 day ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…

4 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting 

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026,…

4 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) 

Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult…

5 days ago